search
Back to results

Comparison of Dexmedetomidine and Midazolam for Prevention of Emergence Delirium in Children

Primary Purpose

Tonsillitis

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Dexmedetomidine
Midazolam
Sponsored by
Eunah Cho, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Tonsillitis

Eligibility Criteria

24 Months - 12 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients undergoing elective tonsillectomy under general anesthesia
  • American society of anesthesiologist physical status 1,2
  • aged from 24 months to 12 years old
  • obtaining written informed consent

Exclusion Criteria:

  • known history of allergy to dexmedetomidine or midazolam
  • renal impairment
  • hepatic impairment
  • long QT syndrome
  • developmental disorder
  • congenital disorder
  • neurologic disorder
  • psychogenic disorder

Sites / Locations

  • Kangbuk Samsung Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Dexmedetomidine group

Midazolam group

Arm Description

Subjects who receive dexmedetomidine for prevention of emergence delirium

Subjects who receive midazolam for prevention of emergence delirium

Outcomes

Primary Outcome Measures

Presence of Emergence Delirium (ED)
During the PACU stay, the patients will be assessed whether the emergence delirium (ED) occurred. It is defined as ED, if the highest score is more than 3 points after five time point measurements by the four-point agitation scale (1=calm, 2=not calm but easily calmed, 3=not easily calmed, moderately agitated, and 4=combative, excited, disoriented). The five time points are the 0 minute, 5 minutes, 10 minutes, 15 minutes and 20 minutes after arrival at the PACU.

Secondary Outcome Measures

Severity of Emergence Delirium
Patients will be scored using the pediatric anesthesia emergence delirium scale. This consists of 5 criteria, each of which is pointed from 0 to 5 according to the severity. Total score stands for the delirium severity.
Emergence time
Time from the discontinuation of the anesthetic gas to extubation.

Full Information

First Posted
November 1, 2017
Last Updated
January 6, 2019
Sponsor
Eunah Cho, MD
search

1. Study Identification

Unique Protocol Identification Number
NCT03337672
Brief Title
Comparison of Dexmedetomidine and Midazolam for Prevention of Emergence Delirium in Children
Official Title
Comparison of Dexmedetomidine and Midazolam for Prevention of Emergence Delirium in Children
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
December 5, 2017 (Actual)
Primary Completion Date
December 17, 2018 (Actual)
Study Completion Date
December 17, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Eunah Cho, MD

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Emergence delirium is a common complication in children after anesthesia. The incidence of emergence delirium is reported upto 50%. Prevention of emergence delirium in children is important not only for the patient safety but also for the satisfaction of the parents. Midazolam is the most commonly used medications for prevention of emergence delirium. However, it might lead to delayed awakening from anesthesia and respiratory depression. In this study, the investigators will evaluate whether dexmedetomidine can be effectively and safely administered for prevention of emergence delirium in children compared to midazolam.
Detailed Description
In this study, seventy patients scheduled for elective tonsillectomy aged from 24 months to 12 years old Anesthesiologists physical status (ASA) class 1 and 2 will be enrolled. The sample size was calculated based on the former study with a type 1 error estimate of 0.05 at 80% power. The proportion in dexmedetomidine group (group D) was assumed to be 0.4 and the proportion in midazolam group (group M) was 0.1. Considering the drop-out rate of 10%, seventy patients in total were needed.The patients will randomly be allocated into the group D or the group M. The group D will receive dexmedetomidine0.3mcg/kg mixed with 0.9% normal saline, 10mL in total. The group M will receive 0.03mg/kg of midazolam mixed with 0.9% normal saline, 10mL in total. Randomization and drug administration will be done by a single anesthesiologist. Assessment of the patient will be done by another anesthesiologist blinded by the group. Five minutes before the end of the surgery, the study drug will be slowly infused for 5 minutes. In the postanesthesia circuit unit (PACU), presence of emergence delirium will be assessed. The emergence delirium will be assessed by the four-point agitation scale. (1 = calm, 2 = not calm but gould be easily calmed, 3 = not easily calmed, moderately agitated or restless, and 4 = combative, exited or disoriented.) Patients with score 3 and 4 will be diagnosed as emergence delirium and treated with intravenous fentanyl 1mcg/kg. Severity of emergence delirium will be assessed with the pediatric anesthesia emergence delirium scale after 10 mins on arrival of PACU. Pain wil be scored by 5-point scale (0 = no pain, 5 = severe pain ever). Time from discontinuation of anesthetic gas to extubate will be recorded. The data will be compared between the groups by the independent t-test or Mann-Whitney test for the continuous variables. Chi-square test or Fisher's exact test will be used for the categorial variables.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tonsillitis

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
70 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexmedetomidine group
Arm Type
Experimental
Arm Description
Subjects who receive dexmedetomidine for prevention of emergence delirium
Arm Title
Midazolam group
Arm Type
Active Comparator
Arm Description
Subjects who receive midazolam for prevention of emergence delirium
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Intervention Description
Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
Primary Outcome Measure Information:
Title
Presence of Emergence Delirium (ED)
Description
During the PACU stay, the patients will be assessed whether the emergence delirium (ED) occurred. It is defined as ED, if the highest score is more than 3 points after five time point measurements by the four-point agitation scale (1=calm, 2=not calm but easily calmed, 3=not easily calmed, moderately agitated, and 4=combative, excited, disoriented). The five time points are the 0 minute, 5 minutes, 10 minutes, 15 minutes and 20 minutes after arrival at the PACU.
Time Frame
0 minute, 5 minutes, 10 minutes, 15 minutes and 20 minutes after arrival at the PACU
Secondary Outcome Measure Information:
Title
Severity of Emergence Delirium
Description
Patients will be scored using the pediatric anesthesia emergence delirium scale. This consists of 5 criteria, each of which is pointed from 0 to 5 according to the severity. Total score stands for the delirium severity.
Time Frame
10 minutes after arrival at the PACU
Title
Emergence time
Description
Time from the discontinuation of the anesthetic gas to extubation.
Time Frame
3 minutes after extubation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Months
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients undergoing elective tonsillectomy under general anesthesia American society of anesthesiologist physical status 1,2 aged from 24 months to 12 years old obtaining written informed consent Exclusion Criteria: known history of allergy to dexmedetomidine or midazolam renal impairment hepatic impairment long QT syndrome developmental disorder congenital disorder neurologic disorder psychogenic disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eunah Cho, M.D.
Organizational Affiliation
Kangbuk Samsung Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kangbuk Samsung Hospital
City
Seoul
ZIP/Postal Code
03181
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Comparison of Dexmedetomidine and Midazolam for Prevention of Emergence Delirium in Children

We'll reach out to this number within 24 hrs